PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 254 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,382,740 | -21.9% | 1,055,500 | +2.0% | 0.87% | -12.2% |
| Q2 2023 | $41,472,450 | -1.6% | 1,035,000 | +0.2% | 0.99% | -1.8% |
| Q1 2023 | $42,140,406 | +5.7% | 1,032,600 | 0.0% | 1.00% | +4.8% |
| Q4 2022 | $39,868,686 | -26.3% | 1,032,600 | +1.5% | 0.96% | -31.4% |
| Q3 2022 | $54,121,000 | -8.8% | 1,017,500 | 0.0% | 1.40% | -19.0% |
| Q2 2022 | $59,320,000 | -22.3% | 1,017,500 | +1.8% | 1.73% | -10.2% |
| Q1 2022 | $76,320,000 | +26.8% | 1,000,000 | 0.0% | 1.92% | +38.2% |
| Q4 2021 | $60,170,000 | +7.4% | 1,000,000 | 0.0% | 1.39% | +18.1% |
| Q3 2021 | $56,000,000 | -10.0% | 1,000,000 | -2.4% | 1.18% | -4.2% |
| Q2 2021 | $62,197,000 | -13.4% | 1,025,000 | 0.0% | 1.23% | -21.6% |
| Q1 2021 | $71,842,000 | +17.1% | 1,025,000 | 0.0% | 1.57% | +20.4% |
| Q4 2020 | $61,336,000 | +1.5% | 1,025,000 | +2.0% | 1.30% | -15.1% |
| Q3 2020 | $60,421,000 | +24.5% | 1,005,000 | +8.6% | 1.53% | +15.2% |
| Q2 2020 | $48,535,000 | +60.8% | 925,000 | +2.8% | 1.33% | +6.7% |
| Q1 2020 | $30,177,000 | -42.1% | 900,000 | -21.7% | 1.25% | -24.2% |
| Q4 2019 | $52,095,000 | +19.0% | 1,150,000 | 0.0% | 1.65% | -5.7% |
| Q3 2019 | $43,781,000 | -19.5% | 1,150,000 | -8.0% | 1.74% | -11.3% |
| Q2 2019 | $54,363,000 | +14.3% | 1,250,000 | 0.0% | 1.97% | +7.3% |
| Q1 2019 | $47,575,000 | -11.5% | 1,250,000 | 0.0% | 1.83% | -27.7% |
| Q4 2018 | $53,775,000 | -15.3% | 1,250,000 | -3.3% | 2.54% | +10.3% |
| Q3 2018 | $63,525,000 | +65.4% | 1,292,479 | +7.9% | 2.30% | +55.7% |
| Q2 2018 | $38,396,000 | +9.6% | 1,198,000 | +6.5% | 1.48% | -1.2% |
| Q1 2018 | $35,044,000 | -30.6% | 1,125,000 | +1.7% | 1.50% | -34.8% |
| Q4 2017 | $50,521,000 | +23.7% | 1,106,700 | +1.7% | 2.29% | +21.6% |
| Q3 2017 | $40,854,000 | -17.8% | 1,088,000 | +4.4% | 1.88% | -24.9% |
| Q2 2017 | $49,727,000 | +9.1% | 1,042,500 | +4.2% | 2.51% | -4.6% |
| Q1 2017 | $45,600,000 | +98.0% | 1,000,000 | +40.3% | 2.63% | +70.7% |
| Q4 2016 | $23,030,000 | +33.5% | 713,000 | +41.5% | 1.54% | +42.6% |
| Q3 2016 | $17,247,000 | +8.2% | 504,000 | +6.7% | 1.08% | -8.4% |
| Q2 2016 | $15,937,000 | -7.9% | 472,500 | +44.7% | 1.18% | -18.6% |
| Q1 2016 | $17,298,000 | -13.4% | 326,500 | +25.6% | 1.45% | -4.2% |
| Q4 2015 | $19,965,000 | +189.1% | 260,000 | +54.8% | 1.51% | +170.2% |
| Q3 2015 | $6,905,000 | +43.6% | 168,000 | +147.1% | 0.56% | +59.5% |
| Q2 2015 | $4,809,000 | +6.7% | 68,000 | +34.0% | 0.35% | -16.8% |
| Q1 2015 | $4,509,000 | -54.4% | 50,750 | -50.2% | 0.42% | -72.4% |
| Q3 2014 | $9,886,000 | +38.4% | 102,000 | +31.2% | 1.53% | +19.4% |
| Q2 2014 | $7,142,000 | +67.3% | 77,750 | +27.5% | 1.28% | +30.1% |
| Q1 2014 | $4,269,000 | +47.1% | 61,000 | +20.8% | 0.98% | -5.0% |
| Q4 2013 | $2,903,000 | – | 50,500 | – | 1.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |